LCQ in Specific Patient Populations Flashcards
6 cards from real LCQ practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 6 LCQ in Specific Patient Populations flashcards as text
How is the LCQ used in clinical drug trials for novel antitussive medications in the US?
Answer: As a primary or secondary patient-reported outcome endpoint
In US clinical trials for antitussive drugs, the LCQ serves as a primary or secondary patient-reported outcome endpoint measuring treatment effect on cough-related quality of life.
For patients with upper airway cough syndrome (UACS), how is the LCQ typically applied?
Answer: To measure QoL at baseline and after treatment of the underlying cause
In UACS (formerly post-nasal drip syndrome), the LCQ measures quality of life impairment at baseline and monitors improvement as nasal pathology is treated.
Why is the LCQ considered suitable for use across diverse chronic cough etiologies?
Answer: Because it measures cough-related QoL impact, which is relevant regardless of cause
The LCQ measures the impact of cough on quality of life rather than the cough's cause, making it applicable across all chronic cough etiologies in the US and globally.
In patients with treatment-refractory chronic cough, LCQ scores are typically:
Answer: Persistently low, reflecting ongoing severe QoL impairment
Treatment-refractory chronic cough patients typically maintain persistently low LCQ scores, indicating sustained quality of life impairment despite treatment attempts.
Has the LCQ been applied in patients with eosinophilic bronchitis?
Answer: Yes — to measure QoL outcomes alongside sputum eosinophil monitoring
The LCQ has been applied in eosinophilic bronchitis research to measure cough-related quality of life alongside inflammatory biomarkers.
In what clinical setting is LCQ use particularly valuable for demonstrating treatment value to US payers?
Answer: Demonstrating patient-reported quality of life improvement to support insurance reimbursement decisions
LCQ data demonstrating meaningful quality of life improvement is increasingly used to support value-based reimbursement arguments for chronic cough treatments with US payers.